Atea Pharmaceuticals, Inc. AVIR
4.41 USD +0.10 (+2.32%)
At closeNov 9, 2026, 5:45 PM EST
4.49 +0.08 +1.82%
After hours · Nov 9, 5:45 PM ET
4.32 Day range 4.48
2.87 52-week range 6.45
- YTD
- +23.53%
- 1 year
- +34.86%
News
benzinga.com CORRECTION: Atea Pharmaceuticals Q3 EPS $(0.40) Beats $(0.42) Estimate Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.42) by 4.76 percent. This is a 24.53 percent increase over losses of…
benzinga.com Atea Pharmaceuticals Q3 2026 Earnings Call Transcript Atea Pharmaceuticals (NASDAQ:AVIR) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…
benzinga.com Atea Pharmaceuticals Q3 EPS $0.40 Beats $(0.42) Estimate Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly earnings of $0.40 per share which beat the analyst consensus estimate of $(0.42) by 195.24 percent. This is a 175.47 percent increase over losses…
globenewswire.com Atea Pharmaceuticals to Host Third Quarter 2026 Financial Results and Business Update Conference Call on November 9, 2026 BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral…
benzinga.com Morgan Stanley Maintains Equal-Weight on Atea Pharmaceuticals, Raises Price Target to $7 Morgan Stanley analyst Matthew Harrison maintains Atea Pharmaceuticals (NASDAQ:AVIR) with a Equal-Weight and raises the price target from $6 to $7.
benzinga.com Atea Pharmaceuticals Says Hepatitis C Drug Matches Gilead's in Pivotal Trial Atea Pharmaceuticals announced positive Phase 3 C-BEYOND trial results for its oral hepatitis C combination therapy vs. Gilead's therapy.- benzinga.com Atea Pharmaceuticals Says Topline Data From C-BEYOND Phase 3 Trial Of Once-daily Fixed-Dose Combination Of Bemnifosbuvir and Ruzasvir for Chronic Hepatitis C Virus Infection Shows Statistical Non-Inferiority Vs. Fixed-Dose Combination Of Sofosbuvir and Velpatasvir In the mITT analysis (n=905, cirrhotic and non-cirrhotic), BEM/RZR achieved a 93.9% sustained virologic response (SVR) rate vs. 94.8% for SOF/VEL (Epclusa) at Week 24, encompassing SVR at 12 weeks…
- benzinga.com Atea Pharmaceuticals Initiates First-in-human Phase 1 Clinical Trial Of AT-587 For Hepatitis E Virus Infection Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral…
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Q32 Bio (NASDAQ:QTTB) stock moved upwards by 44.4% to $16.19 during Friday's after-market session. The company's market cap stands at $213.4 million. China Pharma Holding (AMEX:CPHI) shares…
benzinga.com Atea Pharma Completes Patient Enrollment In C-FORWARD, Phase 3 Clinical Trial Outside North America, Evaluating Regimen Of Bemnifosbuvir And Ruzasvir For Treatment Of Hepatitis C Virus Infection Topline Phase 3 Results from C-FORWARD Expected Around Year-End 2026More Than 880 HCV Treatment-Naïve Patients Enrolled Across 17 Countries Outside North AmericaC-FORWARD and C-BEYOND Represent the…
benzinga.com Atea Pharmaceuticals Q1 2026 Earnings Call: Complete Transcript - benzinga.com Atea Pharmaceuticals Q1 EPS $(0.57) Beats $(0.59) Estimate Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.57) per share which beat the analyst consensus estimate of $(0.59) by 3.39 percent. This is a 42.5 percent decrease over losses of…
benzinga.com Earnings Scheduled For May 12, 2026 
benzinga.com Top 2 Health Care Stocks That May Fall Off A Cliff This Month Momentum warning for health care sector stocks: RSI indicator shows overbought assets. Arcellx (ACLX) and Atea Pharma (AVIR) among top-ranked.
benzinga.com Evercore ISI Group Maintains Outperform on Atea Pharmaceuticals, Raises Price Target to $10 Evercore ISI Group analyst Jonathan Miller maintains Atea Pharmaceuticals (NASDAQ:AVIR) with a Outperform and raises the price target from $6 to $10.
benzinga.com Atea Pharmaceuticals Q4 EPS $(0.57) Misses $(0.53) Estimate Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0.53) by 7.55 percent. This is a 42.5 percent decrease over losses…- benzinga.com Earnings Scheduled For March 5, 2026
benzinga.com Insights Ahead: Atea Pharmaceuticals's Quarterly Earnings - benzinga.com Atea Pharmaceuticals Completes Enrollment Of Over 880 Treatment-naïve Patients In C-BEYOND Phase 3 Trial Of Fixed-dose Combination Bemnifosbuvir And Ruzasvir Compared To Sofosbuvir And Velpatasvir Regime For Hepatitis C Virus; Results Are Expected Mid-year 2026 In addition to C-BEYOND, Atea continues to advance enrollment of treatment-naïve patients in C-FORWARD, a Phase 3 trial evaluating this same FDC regimen in 880 patients at approximately 120 clinical…
benzinga.com Atea Pharmaceuticals Q3 EPS $(0.53) Misses $(0.44) Estimate Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.53) per share which missed the analyst consensus estimate of $(0.44) by 20.45 percent. This is a 43.24 percent decrease over losses…- benzinga.com Earnings Scheduled For November 12, 2025
benzinga.com Atea Pharmaceuticals Earnings Preview - benzinga.com Atea Pharmaceuticals Released New Modeling Data Showing Its Bemnifosbuvir And Ruzasvir Combination Regimen Achieved Near-Complete Inhibition Of HCV Replication And Secretion, With A Predicted Cure Time Of 7–8 Weeks Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral…
- benzinga.com Atea Pharma To Present New Data Supporting Combination Regimen Of Bemnifosbuvir As Potential For HCV Infection Treatment At The Liver Meeting 2025, AASLD Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral…
- benzinga.com Atea Pharmaceuticals Q2 EPS $(0.44) Misses $(0.43) Estimate Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $(0.43) by 2.33 percent. This is a 8.33 percent increase over losses…
- benzinga.com Earnings Scheduled For August 7, 2025
- benzinga.com Atea Begins Global Late-Stage Trial of Oral Hepatitis C Drug Combo Aimed at Easier, Faster Cure Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral…
- benzinga.com Atea Pharmaceuticals Q1 EPS $(0.40) Beats $(0.41) Estimate Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.41) by 2.44 percent. This is a 46.67 percent increase over losses of…
benzinga.com Atea Pharmaceuticals Releases Full Results From Phase 2 Study Of Regimen Of Bemnifosbuvir And Ruzasvir For Treatment Of Hepatitis C Virus, Including Confirmed 98% Sustained Virologic Response At 12 Weeks Post-Treatment After Short 8-Week Treatment Duration For Regimen Full Results from Phase 2 Study Confirmed 98% Sustained Virologic Response at 12 Weeks Post-Treatment (SVR12) After Short 8-Week Treatment Duration for RegimenResults from Phase 1 Study Showed Low…- benzinga.com Atea Pharma Presents Results From Full Cohort Of Patients Enrolled In Phase 2 Study Evaluating Once-daily Combination Of BEM And RZR For Treatment Of Hepatitis C Virus Full Results from Phase 2 Study Confirmed 98% Sustained Virologic Response at 12 Weeks Post-Treatment (SVR12) After Short 8-Week Treatment Duration for RegimenResults from Phase 1 Study Showed Low…
- benzinga.com Morgan Stanley Maintains Equal-Weight on Atea Pharmaceuticals, Lowers Price Target to $6 Morgan Stanley analyst Matthew Harrison maintains Atea Pharmaceuticals (NASDAQ:AVIR) with a Equal-Weight and lowers the price target from $6.2 to $6.
benzinga.com Atea Pharma Cuts Workforce By 25%, Expects $15 Million In Cost Savings, Plans Phase 3 Hepatitis C Trial Atea Pharma posted a Q4 loss of $0.40 per share, cut 25% of its workforce, and is launching a Phase 3 HCV trial while facing analyst skepticism over its drug.- benzinga.com Atea Pharmaceuticals Q4 EPS $(0.40) Misses $(0.37) Estimate Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $(0.37) by 8.11 percent. This is a 14.89 percent increase over losses…
- benzinga.com Earnings Scheduled For March 6, 2025
- benzinga.com Atea Pharmaceuticals Reports Its Cash, Cash Equivalents And Marketable Securities Balance Of $454.7M At December 31, 2024 And A Cash Runway Anticipated Into 2028 Global Phase 3 HCV Program Expected to Initiate in 1Q 2025Potential Best-in-Class Profile of Bemnifosbuvir + Ruzasvir Regimen Supports Opportunity to Disrupt and Expand Global HCV Market of…
- benzinga.com After Failed COVID-19 Drug Trial, Atea Pharmaceuticals Touts Encouraging Data From Mid-Stage Hepatitis C Study Atea Pharmaceuticals reports 98% SVR12 in a Phase 2 hepatitis C study, supporting an eight-week treatment plan with bemnifosbuvir and ruzasvir.
benzinga.com Atea Pharmaceuticals Q3 2024 GAAP EPS $(0.37) Beats $(0.49) Estimate Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0.49) by 24.49 percent. This is a 7.5 percent increase over losses of…
benzinga.com Atea Pharmaceuticals' COVID-19 Treatment Flunks In Late-Stage Study, Blames 'Constantly Evolving' Virus Atea Pharmaceuticals' Phase 3 SUNRISE-3 trial for bemnifosbuvir in COVID-19 patients did not meet the primary endpoint. The company remains focused on its hepatitis C combination therapy.- benzinga.com Adobe, SelectQuote, Similarweb And Other Big Stocks Moving Lower In Friday's Pre-Market Session
- benzinga.com Atea Pharmaceuticals Updates On Global Phase 3 SUNRISE-3 Trial On Bemnifosbuvir For Treatment Of COVID-19; Says Trial Did Not Meet Primary Endpoint The trial did not meet the primary endpoint of a statistically significant reduction in all-cause hospitalization or death through Day 29 in the monotherapy cohort of 2,221 high-risk patients with…
- benzinga.com Atea Pharmaceuticals Announced Publication of Additional Data Further Highlighting Bemnifosbuvir's Metabolic Activation Pathway Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today…
- benzinga.com Morgan Stanley Upgrades Atea Pharmaceuticals to Equal-Weight, Raises Price Target to $6.88 Morgan Stanley analyst Matthew Harrison upgrades Atea Pharmaceuticals (NASDAQ:AVIR) from Underweight to Equal-Weight and raises the price target from $2 to $6.88.
- benzinga.com Atea Pharmaceuticals Q2 2024 GAAP EPS $(0.48) Beats $(0.77) Estimate Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.77) by 37.66 percent.
- benzinga.com Atea Pharmaceuticals Shares Promising Data From Therapy Study For Hepatitis C Virus Atea Pharmaceuticals announces 97% SVR12 in Phase 2 HCV study of bemnifosbuvir. Data shows high efficacy, safety, and low resistance risk.
- benzinga.com Atea Pharmaceuticals Presents Initail Phase 2 Results for Bemnifosbuvir And Ruzasvir Mix In Treating Hepatitis C At The 2024 EASL Congress 97% SVR12 Rate Observed with 8 Weeks of Treatment in Lead-In Cohort of HCV-Infected Patients in Ongoing Phase 2 Clinical Study EASL Presentations Continue to Support Best-in-Class Potential with High…
- benzinga.com Atea Pharmaceuticals Q1 2024 GAAP EPS $(0.75) Misses $(0.61) Estimate Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.75) per share which missed the analyst consensus estimate of $(0.61) by 22.95 percent. This is a 74.42 percent decrease over losses…
- benzinga.com Recap: Atea Pharmaceuticals Q4 Earnings
- benzinga.com Earnings Scheduled For February 28, 2024 Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenue of $1.69 billion.
- benzinga.com Earnings Scheduled For November 8, 2023 Companies Reporting Before The Bell • Flex LNG (NYSE:FLNG) is estimated to report earnings for its third quarter.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 369 companies set new 52-week lows.